52 weeks
Primary objective:~- Describe the characteristics of enrolled severe asthma patients~Secondary objectives:~Assess the control of asthma under dupilumab (Dupixent®) treatment until 1 year~Assess the clinical objectives of the asthma care~Assess comorbidities associated with Type 2 inflammation~Assess safety during the year of treatment